What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
Sun Young Rha mainly investigates Internal medicine, Cancer, Oncology, Renal cell carcinoma and Surgery.
Internal medicine is frequently linked to Gastroenterology in his study.
His biological study spans a wide range of topics, including Survival rate, Cancer research and Bioinformatics.
His research investigates the connection with Oncology and areas like Pathology which intersect with concerns in Survival analysis.
His Renal cell carcinoma research incorporates elements of Targeted therapy, Clinical trial and Everolimus.
His Surgery study integrates concerns from other disciplines, such as Placebo and Capecitabine.
His most cited work include:
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study (810 citations)
- External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study (480 citations)
- Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes (471 citations)
What are the main themes of his work throughout his whole career to date?
Sun Young Rha focuses on Internal medicine, Cancer, Oncology, Cancer research and Surgery.
His Gastroenterology research extends to the thematically linked field of Internal medicine.
His work carried out in the field of Cancer brings together such families of science as Survival rate, Pathology and Stage.
Sun Young Rha has included themes like Clinical trial, Phases of clinical research, Trastuzumab, Capecitabine and Advanced gastric cancer in his Oncology study.
His Cancer research research integrates issues from Cancer cell, Cell culture, Immunology and Carcinogenesis.
His Surgery study combines topics in areas such as Stomach cancer and Adverse effect.
He most often published in these fields:
- Internal medicine (50.77%)
- Cancer (40.00%)
- Oncology (33.71%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (50.77%)
- Cancer (40.00%)
- Cancer research (20.56%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Internal medicine, Cancer, Cancer research, Oncology and Chemotherapy.
His research on Internal medicine frequently links to adjacent areas such as Gastroenterology.
His Cancer research includes themes of Surgical oncology and Cohort.
The study incorporates disciplines such as Cell culture, Cancer cell, Apoptosis and T cell, Immune system in addition to Cancer research.
His research in Oncology tackles topics such as Pembrolizumab which are related to areas like Nivolumab.
His research integrates issues of Regimen, Trastuzumab and Gene expression profiling in his study of Chemotherapy.
Between 2017 and 2021, his most popular works were:
- Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: Phase 1b results from the JAVELIN Solid Tumor trial (31 citations)
- Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. (30 citations)
- Marked Loss of Muscle, Visceral Fat, or Subcutaneous Fat After Gastrectomy Predicts Poor Survival in Advanced Gastric Cancer: Single-Center Study from the CLASSIC Trial (25 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
His primary areas of investigation include Internal medicine, Cancer, Oncology, Gastroenterology and Cancer research.
All of his Internal medicine and Neutropenia, Chemotherapy, Sunitinib, Oxaliplatin and Hazard ratio investigations are sub-components of the entire Internal medicine study.
His Cancer study combines topics from a wide range of disciplines, such as Exosome, Surgical oncology, Surgery, Cytokine and Tolerability.
The various areas that Sun Young Rha examines in his Oncology study include Carcinoembryonic antigen, Clinical trial, Subgroup analysis and Synovial sarcoma.
His studies deal with areas such as Survival rate, Nausea, Adverse effect and Progression-free survival as well as Gastroenterology.
His Cancer research research incorporates elements of Cell culture, Apoptosis, Immune system and Exon.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
